Financial Performance - Net sales for Q1 fiscal 2026 were $343 million, representing a 1% increase compared to the same quarter last year[5]. - GAAP gross margin decreased to 28.0%, down 70 basis points year-over-year, while non-GAAP gross margin fell to 30.0%, down 80 basis points[5]. - GAAP diluted EPS was $0.04, a decrease from $0.10 in the year-ago quarter, while non-GAAP diluted EPS remained stable at $0.49[5]. - The company expects net sales growth of 6% year-over-year for fiscal 2026, with a margin of +/-10%[8]. - Projected GAAP gross margin for fiscal 2026 is 27% +/- 1%, while non-GAAP gross margin is expected to be 29% +/- 1%[8]. - Operating expenses are forecasted at $307 million +/- $10 million for GAAP, and $250 million +/- $10 million for non-GAAP[8]. - Operating income for Q1 was $19.6 million, compared to $12.4 million in the previous quarter[6]. - Net income attributable to Penguin Solutions for Q1 was $5.3 million, down from $9.4 million in the year-ago quarter[6]. - Non-GAAP operating income was reported at $41.528 million, an increase from $39.170 million in the previous quarter and $40.918 million year-over-year[25]. - The GAAP operating margin for the latest quarter was 5.7%, compared to 3.7% in the previous quarter and 5.1% year-over-year[25]. Segment Performance - Advanced Computing segment net sales were $151.5 million, Integrated Memory segment sales were $136.5 million, and Optimized LED segment sales were $55.1 million in Q1[6]. - Advanced Computing segment sales reached $151.452 million, up from $138.336 million in the previous quarter but down from $177.426 million year-over-year[24]. - Integrated Memory segment sales increased to $136.521 million from $132.159 million quarter-over-quarter and significantly up from $96.706 million year-over-year[24]. Cash Flow and Assets - Net cash provided by operating activities was $31,058,000 for the three months ended November 28, 2025, compared to a net cash used of $70,432,000 in the previous quarter[28]. - Total current assets as of November 28, 2025, were $1,067,014,000, slightly up from $1,064,227,000 as of August 29, 2025[27]. - Cash and cash equivalents increased to $461,451,000 as of November 28, 2025, from $453,754,000 as of August 29, 2025[27]. - Total liabilities decreased to $993,726,000 as of November 28, 2025, from $1,008,973,000 as of August 29, 2025[27]. - Inventories decreased to $213,205,000 as of November 28, 2025, from $255,182,000 as of August 29, 2025[27]. Equity and Earnings - Total stockholders' equity decreased to $401,759,000 as of November 28, 2025, from $405,517,000 as of August 29, 2025[27]. - Non-GAAP net income attributable to Penguin Solutions increased to $32,391,000 for the three months ended November 28, 2025, up from $28,843,000 in the previous quarter[26]. - GAAP net income for the three months ended November 28, 2025, was $5,270,000, compared to $9,431,000 for the previous quarter[26]. - Adjusted EBITDA for the three months ended November 28, 2025, was $45,236,000, compared to $43,419,000 in the previous quarter[26]. Corporate Actions - The company plans to divest its remaining 19% interest in Zilia Technologies for $46.08 million, expected to close by April 28, 2026[3]. - The company completed the redomiciliation from the Cayman Islands to Delaware on June 30, 2025, resulting in a change of its publicly traded parent company[21].

Revenue Expectations - Newton Golf Company expects 2025 revenue to exceed the previously issued guidance range of $7.0 million to $7.5 million[6] Company Classification - The company is classified as an emerging growth company under the Securities Act of 1933[3] Fiscal Year Information - The fiscal year ended December 31, 2025, with preliminary financial results announced on January 6, 2026[4]

Financial Performance - Net sales for the three months ended November 30, 2025, increased by $6.6 million to $79.4 million, compared to $72.8 million in the same period of the prior year, representing an increase of 9.0%[111] - The Company reported a net loss of $6.4 million for the three months ended November 30, 2025, a decrease of $4.4 million compared to a net loss of $10.7 million in the same quarter of the prior year[109] - For the six months ended November 30, 2025, net sales increased by $14.8 million to $155.1 million, compared to $140.3 million in the same period of the prior year, representing an increase of 10.6%[111] - The company reported a net loss of $17.3 million and $23.5 million for the six months ended November 30, 2025 and 2024, respectively[131] Revenue Growth - Med Tech revenue grew by 13.0% in the second quarter of fiscal year 2026, driven by Auryon, NanoKnife, and thrombus management products[108] - The Company’s Med Device revenue grew by 6.0% in the second quarter of fiscal year 2026, driven by growth in Core, Ports, and Venous product lines[108] - Increased sales of Auryon contributed $2.6 million and $5.3 million for the three and six months ended November 30, 2025, respectively[114] Margins - Gross margin increased by 160 basis points to 56.4% for the three months ended November 30, 2025, compared to 54.8% in the same period of the prior year[111] - Med Tech gross margin increased to 65.3% for the three months ended November 30, 2025, up from 63.7% in the same period of the prior year[115] - The Med Device segment gross margin increased by $1.7 million and $2.6 million for the three and six months ended November 30, 2025, compared to the same period in the prior year[117] Expenses - Research and development (R&D) expense increased by $1.3 million and $1.5 million for the three and six months ended November 30, 2025, respectively[120] - Selling and marketing (S&M) expense rose by $1.1 million and $3.6 million for the three and six months ended November 30, 2025, respectively[121] - General and administrative (G&A) expense decreased by $0.2 million for the three months but increased by $1.3 million for the six months ended November 30, 2025[122] Cash and Debt Position - Cash and cash equivalents totaled $41.6 million as of November 30, 2025, down from $55.9 million as of May 31, 2025[128] - Cash used in operating activities was $11.3 million and $15.8 million for the six months ended November 30, 2025 and 2024, respectively[131] - As of November 30, 2025, the Company had no outstanding debt, indicating a strong financial position[137] - The Company has a $25.0 million secured revolving credit facility with interest rates based on SOFR plus 0.1% or an alternate base rate, with no amounts outstanding as of November 30, 2025[138] Risk Management - Approximately 4.6% of the company's sales for the six months ended November 30, 2025, were denominated in foreign currencies, exposing profitability to currency fluctuations[136] - The Company mitigates credit risk by maintaining cash and cash equivalents at various institutions and regularly evaluating their credit standings[139] - No single customer accounts for more than 10% of total sales, reducing concentration of credit risk in trade accounts receivable[140] - The standard payment terms for customers are 30 to 90 days from invoicing, minimizing significant financing provided to customers[140] - The Company does not foresee significant credit risk associated with outstanding accounts receivable, relying on the financial stability of its customers[140] Future Outlook - The Company expects to grow by expanding geographically, penetrating new markets, and introducing new products[106] - The backlog at November 30, 2025, was $0.4 million, primarily impacting sales of Core products[112] - Acquisition, restructuring, and other items, net, decreased by $2.2 million and $3.8 million for the three and six months ended November 30, 2025, respectively[125] - The effective tax rate for the three months ended November 30, 2025, was 0.1%, compared to 1.0% for the same period in the prior year[127]

Financial Position - As of December 31, 2025, Compass Therapeutics, Inc. estimated cash, cash equivalents, and marketable securities to be approximately $209 million[6] - The reported amount is unaudited and preliminary, subject to changes upon completion of financial closing procedures[6] - The financial statements for the year ended December 31, 2025, will reflect the finalized amounts[6] Corporate Information - The company provided a corporate update in a press release dated January 6, 2026[5] - The company is listed on the NASDAQ Capital Market under the trading symbol CMPX[2] - The company’s principal executive offices are located in Boston, Massachusetts[1] Company Classification and Compliance - The report indicates that Compass Therapeutics is not currently classified as an emerging growth company[3] - The company has not elected to use the extended transition period for complying with new or revised financial accounting standards[3] Performance and Future Guidance - The report does not provide specific performance metrics or future guidance at this time[4] - There are no details on new products, technologies, market expansion, or mergers and acquisitions in the current report[4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K _____________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2026 _____________________________________ EDIBLE GARDEN AG INCORPORATED (Exact name of registrant as specified in its charter) _____________________________________ | Delaware | 001-41371 | 85-0558704 | | --- | --- | --- | | (State or other juri ...

Financial Performance - Cash and liquidity increased by approximately 65% during Q4 2025, exceeding $100 million, which is above the high end of the company's guidance range[5] Project Development - The company announced the start of construction of the SOSA Energy Center, a 150 MW/300 MWh battery energy storage system located in Madison County, Texas[6]

Financial Performance - Net sales for Q2 FY 2026 were $79.4 million, an increase of 8.8% year-over-year[2] - Med Tech net sales reached $35.7 million, reflecting a 13.0% increase from the prior year[8] - Adjusted EBITDA for Q2 FY 2026 was $5.9 million, up from $3.1 million in Q2 FY 2025[14] - Gross margin improved to 56.4%, a 170 basis point increase compared to Q2 FY 2025[11] - Auryon sales were $16.3 million, an 18.6% increase, while NanoKnife sales grew by 22.2% to $7.3 million[9] - The company raised its full-year FY 2026 net sales guidance to $312 - $314 million from the previous $308 - $313 million[22] - Net sales for the three months ended November 30, 2025, were $79,433,000, an increase of 9% compared to $72,845,000 for the same period in 2024[35] - For the six months ended November 30, 2025, net sales were $155,144,000, representing a 10.6% increase from $140,336,000 in the same period of 2024[38] - The company’s total net sales for the six months reached $155,144,000, reflecting a 10.6% growth compared to the same period last year[65] - Total net sales for the company reached $44,783,000, marking a 12.2% increase compared to the prior year[62] Profitability and Loss - The net loss for the three months ended November 30, 2025, was $6,350,000, a 41% improvement from a net loss of $10,738,000 in the prior year[35] - Adjusted net loss for the three months ended November 30, 2025, was $59,000, significantly improved from an adjusted net loss of $1,742,000 in the prior year[40] - The diluted loss per share for the three months ended November 30, 2025, was $0.15, compared to $0.26 in the same period of 2024[40] - The company reported an adjusted net loss of $4,238,000 for the six months ended November 30, 2025, compared to an adjusted net loss of $6,137,000 for the same period in 2024[47] - The diluted loss per share for the six months ended November 30, 2025, was $0.42, improving from $0.58 in the prior year[47] Operating Expenses - Research and development expenses increased to $7,768,000 for the three months ended November 30, 2025, compared to $6,434,000 in the same period of 2024[35] - Total operating expenses for the six months ended November 30, 2025, were $103,421,000, an increase from $100,822,000 in the same period of 2024[38] - Acquisition, restructuring, and other items totaled $3,635,000 for the three months ended November 30, 2025, down from $5,868,000 in the same period of 2024[54] Cash and Liabilities - The company ended Q2 FY 2026 with $41.6 million in cash and cash equivalents, up from $38.8 million at the end of Q1 FY 2026[15] - Cash and cash equivalents decreased to $41,638,000 from $55,893,000 as of May 31, 2025[71] - Total liabilities decreased to $93,348,000 from $97,174,000 as of May 31, 2025[71] Strategic Developments - FDA IDE approval was received for the APEX-Return study, evaluating the AlphaReturn Blood Management System[16] - The PAVE clinical study received FDA IDE approval to assess the AngioVac System for right-sided infective endocarditis[17] - Jim Clemmer announced his intention to retire during FY 2027, initiating a search for a successor[24] - The company is undergoing strategic adjustments related to the sale of certain business segments, which may impact future financial performance[35] - The company anticipates continued growth in adjusted EBITDA and net sales as it executes its strategic initiatives and product discontinuations[51] Segment Performance - The Med Tech segment reported sales of $35,653,000, a 13% increase from $31,554,000 in the prior year[59] - The Med Device segment generated $43,780,000 in sales, reflecting a 6% increase from $41,291,000 in the previous year[59] - International sales grew by 16.4% to $11,839,000, compared to $10,167,000 in the same quarter of 2024[59] - Med Tech segment reported net sales of $23,286,000 for the three months ended November 30, 2024, reflecting a 15.8% increase compared to the previous year[62] - Med Device segment achieved net sales of $21,497,000 for the same period, representing an 8.6% growth year-over-year[62] - For the six months ended November 30, 2024, Med Tech net sales were $70,914,000, up 19.1% year-over-year[65] - The company’s gross margin for the total segment was 56.4% for the three months ended November 30, 2024[62] - Gross margin for the Med Tech segment was 65.3%, while the Med Device segment reported a gross margin of 49.1%[62]

Financial Reporting and Internal Controls - As of September 30, 2025, the company has engaged a qualified financial and accounting advisory team to strengthen its financial reporting function and internal controls [123]. - The company has material weaknesses in its internal controls over financial reporting, which could adversely affect its business and the trading price of its Ordinary Shares [124]. - The company expects to incur significant legal, accounting, and compliance costs as a public company, particularly after it no longer qualifies as an "emerging growth company" [139]. - The company’s auditor is based in Manhattan, New York, but faces challenges in fully cooperating with PCAOB due to Chinese regulations [146]. - The SEC has implemented rules requiring increased disclosures for issuers unable to be inspected by PCAOB, which could impact investor confidence [148]. Securities and Market Risks - The company has a substantial number of convertible securities outstanding, including Series A-1, Series A-2, Series B-1, and Series B-1 warrants, issued in a $100 million private placement on October 10, 2025 [127]. - The company is subject to Nasdaq Listing Rules, which require compliance with minimum stockholders' equity and other criteria to maintain its listing [129]. - The company received a notice from Nasdaq regarding non-compliance with the Minimum Bid Price Rule, with a compliance period until September 29, 2025 [158]. - If the company fails to regain compliance by March 30, 2026, it may face delisting from Nasdaq [159]. - The company may face delisting or trading restrictions under the Holding Foreign Companies Accountable Act (HFCAA) if the PCAOB cannot inspect its audit documentation located in mainland China [145]. - The market price of the company’s Class A Ordinary Shares may be volatile, influenced by various external factors [163]. - The market for Class A Ordinary Shares is expected to remain more volatile than that of seasoned issuers for the indefinite future, potentially leading to securities litigation [164]. - The company may lose visibility in financial markets if analysts cease coverage or publish negative reports, affecting share price and trading volume [161]. Shareholder Rights and Corporate Governance - Anti-takeover provisions in the company's memorandum and articles of association may discourage or delay changes in control that shareholders may favor [141]. - Class A Ordinary Shares have one vote per share, while Class B Ordinary Shares have 50 votes per share, significantly limiting the influence of Class A shareholders on corporate matters [165]. Financial Management and Risks - The Group limits credit risk by transacting with broker-dealers, banks, and regulated exchanges that have high credit ratings [464]. - Liquidity risk is managed by monitoring liquid capital and maintaining adequate cash and bank balances to finance operations [465]. - Interest rate risk is considered minimal as cash held with banks is short-term, with terms less than one month [466]. - Inflation has not had a material impact on the Group's results of operations in recent years [467]. - As of September 30, 2023, the Group has no significant foreign currency risk as most transactions are denominated in Hong Kong dollar or U.S. dollar, with minimal exposure due to the peg between the two currencies [462]. Dividend Policy - The company does not intend to pay dividends for the foreseeable future, opting to retain earnings for business operations and expansion [160].

Financial Results Release - Wesbanco, Inc. will release its financial results for Q4 2025 after market close on January 27, 2026[6] - A conference call to discuss the Q4 2025 financial results is scheduled for January 28, 2026, at 9:00 a.m. ET[6]

Financial Results Announcement - Wesbanco, Inc. will release its financial results for Q4 2025 after market close on January 27, 2026[6] - A conference call to discuss the Q4 2025 financial results is scheduled for January 28, 2026, at 9:00 a.m. ET[6] - The press release regarding the earnings announcement is attached as Exhibit 99.1[7]